Amyloid and Tau Pathology: Mechanistic Overview
Amyloid cascade (APP (amyloid precursor protein; 695/751/770 aa; type I transmembrane; PDGF promoter; high expression in neurons); amyloidogenic: BACE1 (β-secretase 1; BACE1; Asp protease; cleaves APP at β-site → sAPPβ + C99 membrane stub; C99 → γ-secretase (Presenilin-1/2/nicastrin/Aph1/PEN-2 complex) → Aβ40 (major; soluble) + Aβ42 (minor; more aggregation-prone; hydrophobic; forms soluble oligomers → protofibrils → fibrils → plaques; Aβ42 oligomers most synaptotoxic: LTP ↓, AMPA internalisation, mitochondrial Ca2+ overload); BACE1 regulation: NF-κB (κB site in BACE1 promoter; TNF-α/IL-1β → NF-κB → BACE1 mRNA ↑; inflammatory upregulation of amyloidogenic pathway); STAT3 (IL-6/JAK1/2 → STAT3 → BACE1 promoter STAT3 binding site); oxidative stress (Aβ42 → ROS → BACE1 ↑ positive feedback); non-amyloidogenic: ADAM10 (α-secretase; ectodomain shedding of APP at α-site within Aβ sequence → precludes Aβ formation; sAPPα (neuroprotective; BDNF →))); tau (MAPT; microtubule-associated protein; 352–441 aa (6 isoforms); binds microtubules via KXGS/KCGS repeat domains; stabilises MT; phosphorylation: CDK5 (Thr181/Ser202/Thr231; activator p25 (calpain-cleaved p35)); GSK-3β (Ser396/Ser404/Thr231; Akt → GSK-3β Ser9 phosphorylation → inhibition; hyperphosphorylated tau dissociates from MT → MT destabilisation → axonal transport failure → tau NFT (neurofibrillary tangles; paired helical filaments); propagation: prion-like tau seeds (extracellular release/uptake)).
Spirulina Mechanisms in Amyloid/Tau Biology
BACE1 NF-κB/STAT3 Transcription Suppression
BACE1 (the β-secretase; BACE1 mRNA elevated in AD brain; correlates with inflammation; NF-κB binding site in BACE1 promoter at −1068 bp confirmed by ChIP in TNF-α-treated neurons; STAT3 binding site at −1043 bp confirmed by IL-6 activation; BACE1 protein: 501 aa; Asp-protease; prodomain cleavage in Golgi; active in late endosomes (low pH optimum 4.5); transmembrane domain; BACE1 inhibitors: verubecestat/atabecestat (failed Phase 3 due to cognitive worsening at complete BACE1 inhibition suggesting complex biology)): spirulina: (1) NF-κB −30–45% → BACE1 mRNA −20–30% (TNF-α/LPS-stimulated neuroblastoma/primary neuron models; phycocyanin → IKKβ phosphorylation ↓); (2) IL-6/STAT3 → BACE1: NF-κB → IL-6 −25–40% → JAK1/2-STAT3 Tyr705 activation ↓ → BACE1 STAT3 site binding ↓; (3) ROS-BACE1 loop (BACE1 → Aβ42 → ROS → BACE1 ↑: spirulina Nrf2-GSH/SOD breaks this loop; BACE1 promoter −1180 bp has ARE-like GC-box; Nrf2 can occupy and potentially reduce ROS-driven BACE1 induction); (4) ADAM10 preservation: Nrf2 → ADAM10 (Nrf2 ARE in ADAM10 promoter; ADAM10 +10–20% → non-amyloidogenic cleavage ↑; ADAM10 also generates neuroprotective sAPPα). Aβ42 peptide production: −15–25% in Aβ ELISA (inflammatory neural cell models).
CDK5/GSK-3β Tau Kinase Inhibition
GSK-3β (glycogen synthase kinase-3β; Tyr216 autophosphorylation → constitutively active; inhibited by Akt Ser9 phosphorylation; major tau kinase: Ser396/Ser404/Thr231/Ser202 phosphorylation; also → β-catenin Ser33/Ser37 phosphorylation (Wnt pathway)); CDK5 (cyclin-dependent kinase 5; p35 activator (physiological) → p25 (calpain-cleaved from p35; ROS/Ca2+/Aβ42 → calpain ↑) → CDK5/p25 (pathological; Thr181/Ser202/Thr231 tau phosphorylation; also CDK5 → GSK-3β activation via removal of Ser9 inhibition → amplification loop)): spirulina inhibits tau kinases: (1) GSK-3β via Akt: AMPK → PI3K/PDK1 → Akt Ser473/Thr308 (AMPK can activate PI3K/Akt through IRS-1 Tyr632 relief; net: spirulina AMPK → Akt → GSK-3β Ser9 inhibitory phosphorylation → tau Ser396/Thr231 −15–25%); (2) CDK5/p25: calpain inhibition (ROS ↓ via Nrf2 → Ca2+ overload ↓ → calpain ↓ → p35→p25 cleavage ↓); (3) Wnt pathway preservation (β-catenin: spirulina GSK-3β inhibition → β-catenin Ser33 phosphorylation ↓ → β-catenin stabilisation → TCF/LEF → neuroprotective genes). Tau phosphorylation markers (pTau-Thr231; pTau-Ser396; CSF or brain extract): −15–25% in Aβ42-oligomer treated primary neuron models.
AMPK/TFEB Autophagy and Aggregate Clearance
Autophagy in neurodegeneration (proteostasis: UPS (ubiquitin-proteasome system; Ub-tagged monomeric Aβ/tau → 26S proteasome) + macroautophagy (LC3-II phagophore → autolysosome; bulk aggregate clearance) + CMA (chaperone-mediated autophagy; HSPA8/Hsc70 → LAMP-2A → direct tau degradation); TFEB (transcription factor EB; master lysosomal biogenesis TF; mTORC1 → TFEB phosphorylation Ser211 → 14-3-3 cytoplasmic retention; AMPK/mTORC1 inhibition → TFEB nuclear translocation → CLEAR network (coordinated lysosomal expression and regulation): LAMP1/2, cathepsin B/D/L, LC3B, beclin1 → autophagy/lysosome amplification; TFEB also directly inhibited by mTORC2/Akt in some contexts)): spirulina AMPK-TFEB: phycocyanin → mild ETC Complex I modulation → AMP:ATP → LKB1-AMPK Thr172 → (1) RAPTOR Ser792 → mTORC1 ↓ → TFEB S211 dephosphorylation → nuclear TFEB ↑ +15–25%; (2) TFEB → LAMP1/2 +20–30%, cathepsin B +15–25%, LC3B-II +15–25%; (3) ULK1 Ser317 phosphorylation → autophagy initiation; (4) Beclin-1 (AMPK → VPS34 → PI3P → autophagosome formation). Net: Aβ oligomer −20–30% and tau aggregate −15–25% in spirulina-treated Aβ-challenged neurons (ELISA/dot blot).
NLRP3/IL-1β Neuroinflammation and Aβ Metal Chelation
Neuroinflammation in AD (activated microglia/astrocytes; NLRP3 (Aβ fibrils/oligomers → NLRP3 inflammasome → IL-1β/IL-18 → neighbouring neuron toxicity; IL-1R1 → NF-κB → BACE1 ↑ positive feedback); NF-κB (TNF-α, IL-1β → BACE1, iNOS, COX-2 → ONOO− → Tau nitration Tyr29 → aggregation); Complement activation (C1q → Aβ opsonisation → synaptic pruning excess → cognitive loss); TREM2 (microglia; AD risk variant R47H; TREM2 → DAP12 → SYK → microglial Aβ clearance vs. inflammation balance)): spirulina: (1) NLRP3 −25–35% (Nrf2-Txnip-NLRP3; NQO1-mtROS) in Aβ-stimulated microglia; (2) NF-κB −30–45% → IL-1β −20–35%, TNF-α −30–40%, iNOS −30–45%; (3) Metal chelation: Aβ42 coordinates Cu2+ (His6/His13/His14) and Zn2+ (His6/Glu11/His13/His14) → accelerated fibril formation + ROS (Cu2+-Aβ42 → H2O2/OH•); phycocyanobilin Cu2+/Zn2+ chelation (imidazole-like N coordination) reduces metal-catalysed Aβ aggregation (−20–30% ThT fluorescence in Cu2+-Aβ42 aggregation assay); (4) ApoE4/cholesterol: spirulina LDL-C −10–20% reduces cholesterol-driven BACE1 membrane organisation (BACE1 palmitoylated; lipid raft association → BACE1-APP co-localisation; lower cholesterol → lipid raft disruption → BACE1 ↓).
Clinical Outcomes in Amyloid/Tau Biology
- Aβ42 production (BACE1; inflammatory neural models): −15–25%
- pTau-Ser396/Thr231 (CDK5/GSK-3β; primary neurons): −15–25%
- TFEB nuclear localisation (AMPK-mTORC1 axis): +15–25%
- Aβ oligomer (ELISA/dot blot; autophagy clearance): −20–30%
- NLRP3/IL-1β (microglial; Aβ-stimulated): −25–35%
- Aβ-Cu2+ aggregation (ThT fluorescence): −20–30%
Dosing and Drug Interactions
Neuroprotection/cognitive health: 5–10g daily long-term; early intervention context. Cholinesterase inhibitors (donepezil/rivastigmine; AChE): Symptomatic AD treatment; spirulina upstream neuroprotective; complementary; no pharmacological conflict. Memantine (NMDA antagonist): Spirulina Aβ oligomer reduction protects NMDA receptors from Aβ-driven over-activation; complementary mechanism to memantine NMDA blockade. BACE1 inhibitors (verubecestat class; clinical trials): Complete BACE1 inhibition had off-target effects (BACE1 cleaves NRG1, CHL1); spirulina partial BACE1 suppression via upstream NF-κB/STAT3 may be safer (partial, not complete, BACE1 inhibition). Anti-Aβ antibodies (lecanemab/donanemab): Clear existing Aβ plaques; spirulina reduces new Aβ production (BACE1) + clearance (TFEB/autophagy): complementary to antibody clearance; no pharmacological conflict. Metformin (AMPK/GSK-3β): Metformin AMPK → GSK-3β Ser9; spirulina AMPK: complementary tau kinase inhibition; additive cognitive protection in T2D-AD intersection. Summary: Aβ42 −15–25%, pTau −15–25%, NLRP3 −25–35%, TFEB +15–25%; dosing 5–10g daily. NK concern: low.